AMNEAL PHARMACEUTICALS, INC. $AMRX Shares Bought by Dark Forest Capital Management LP

Key Points

• Dark Forest Capital Management LP significantly increased its stake in Amneal Pharmaceuticals by 3,256.2%, acquiring 499,707 shares valued at approximately $4.19 million.
• Institutional investors collectively own 31.82% of Amneal Pharmaceuticals, with notable increases in holdings by Vanguard Group and Invesco during the first quarter.
• Amneal Pharmaceuticals reported earnings of $0.23 per share, exceeding analysts' expectations, and set a full-year 2025 guidance of 0.700-0.750 EPS.

Dark Forest Capital Management LP raised its position in AMNEAL PHARMACEUTICALS, INC. (NASDAQ:AMRX - Free Report) by 3,256.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 499,707 shares of the company's stock after acquiring an additional 484,818 shares during the period. Dark Forest Capital Management LP owned approximately 0.16% of AMNEAL PHARMACEUTICALS worth $4,188,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in AMRX. GAMMA Investing LLC lifted its stake in shares of AMNEAL PHARMACEUTICALS by 5,975.0% in the 1st quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock worth $26,000 after acquiring an additional 3,107 shares during the period. Headlands Technologies LLC acquired a new stake in shares of AMNEAL PHARMACEUTICALS in the first quarter valued at about $31,000. Amalgamated Bank lifted its stake in shares of AMNEAL PHARMACEUTICALS by 33.0% in the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after purchasing an additional 1,367 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of AMNEAL PHARMACEUTICALS in the fourth quarter valued at about $52,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of AMNEAL PHARMACEUTICALS in the fourth quarter valued at about $107,000. Institutional investors and hedge funds own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on AMRX. The Goldman Sachs Group began coverage on shares of AMNEAL PHARMACEUTICALS in a research note on Friday, June 6th. They issued a "buy" rating and a $12.00 price objective for the company. Wall Street Zen cut shares of AMNEAL PHARMACEUTICALS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $11.60.

AMNEAL PHARMACEUTICALS Stock Up 0.7%

Shares of AMRX traded up $0.07 during mid-day trading on Friday, hitting $9.62. The company had a trading volume of 1,273,897 shares, compared to its average volume of 1,583,692. The business's 50-day simple moving average is $8.67 and its 200-day simple moving average is $8.13. AMNEAL PHARMACEUTICALS, INC. has a 1-year low of $6.68 and a 1-year high of $9.79. The stock has a market cap of $3.02 billion, a PE ratio of 962.96 and a beta of 1.19.

AMNEAL PHARMACEUTICALS (NASDAQ:AMRX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. AMNEAL PHARMACEUTICALS had a net margin of 0.12% and a negative return on equity of 189.49%. AMNEAL PHARMACEUTICALS has set its FY 2025 guidance at 0.700-0.750 EPS. On average, sell-side analysts expect that AMNEAL PHARMACEUTICALS, INC. will post 0.53 earnings per share for the current year.

Insider Activity

In other AMNEAL PHARMACEUTICALS news, EVP Andrew S. Boyer sold 279,244 shares of the business's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the completion of the sale, the executive vice president owned 152,426 shares in the company, valued at $1,429,755.88. The trade was a 64.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director John Kiely sold 32,000 shares of the business's stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $9.23, for a total transaction of $295,360.00. Following the sale, the director owned 225,433 shares of the company's stock, valued at approximately $2,080,746.59. The trade was a 12.43% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 609,206 shares of company stock valued at $5,700,625. 26.56% of the stock is currently owned by company insiders.

AMNEAL PHARMACEUTICALS Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.